drugset / Trial / NCT00430898
Basiliximab in Moderate to Severe Ulcerative Colitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.
Timeline
- Start
- 2007-01
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Basiliximab | Monoclonal antibody | 20 mg | Intravenous |
| Subject | Basiliximab | Monoclonal antibody | 40 mg | Intravenous |